Cancer Research Meeting Calendar  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 1123-1128, March 1, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by List, J.
Right arrow Articles by Grimm, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by List, J.
Right arrow Articles by Grimm, E. A.

Cytokine Responses to Intraventricular Injection of Interleukin 2 into Patients with Leptomeningeal Carcinomatosis: Rapid Induction of Tumor Necrosis Factor {alpha}, Interleukin 1ß, Interleukin 6, {gamma}-Interferon, and Soluble Interleukin 2 Receptor (Mr 55,000 Protein)1

J. List, R. P. Moser, M. Steuer, W. G. Loudon, J. B. Blacklock and E. A. Grimm2

Departments of Tumor Biology [J. L., W. G. L., E. A. G.] and Neurosurgery [R. P. M., M. S., J. B. B.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Interleukin 2 (IL-2) is a potent immunostimulant that causes the release of secondary cytokines and the production of lymphokine-activated killer cells. We investigated the cellular and cytokine responses to injection of recombinant human IL-2 into the human cerebrospinal fluid of 11 patients with metastatic tumors involving the spinal or cerebral leptomeninges. After initial intraventricular IL-2 administration (1.25 x 105 to 2 x 106 Cetus units/injection), cerebrospinal fluid samples were collected at intervals from 0 to 24 h. Enzyme-linked immunosorbent assay results indicated that IL-2 levels gradually decreased during the first 24 h, with an average t1/2 between 4 and 8 h. Induction of tumor necrosis factor {alpha}, interleukin 1ß, interleukin 6, {gamma}-interferon, and interleukin 2 receptor (p55) was also assessed by enzyme-linked immunosorbent assay. Tumor necrosis factor {alpha} and interleukin 6 levels peaked at 2 to 4 h and 4 to 6 h, with concentrations between 71 to 1,714 pg/ml and 942 to 10,500 pg/ml, respectively. Interleukin 1ß, {gamma}-interferon, and soluble IL-2 receptor peaked later, during 6 to 12 h; the levels achieved were 234 pg/ml, 25 NIH units/ml, and 207 units/ml, respectively. All cytokine concentrations returned to near baseline between 12 and 24 h; however, the soluble IL-2 receptor levels remained elevated. Additional observations included a rapid influx of neutrophilic leukocytes, followed by a prolonged presence of lymphocytes. These data indicate a broad and complex potential of the immune response in the central nervous system, as well as further define the cytokine cascade in response to IL-2 alone.

1 The work was supported in part by a gift from the Dunn Foundation, Houston, TX. J. L. was supported by Grant 482/1-1 from the Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany.

2 To whom requests for reprints should be addressed, at Department of Tumor Biology, Box 79, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030.

Received 9/ 3/91. Accepted 12/ 5/91.




This article has been cited by other articles:


Home page
EndocrinologyHome page
G. Chen, W. L. Castro, H.-H. Chow, and S. Reichlin
Clearance of 125I-Labeled Interleukin-6 from Brain into Blood Following Intracerebroventricular Injection in Rats
Endocrinology, November 1, 1997; 138(11): 4830 - 4836.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.